Features Partner Sites Information LinkXpress
Sign In
Demo Company

Suppressing HIV Infection with Soybean Compound

By BiotechDaily International staff writers
Posted on 14 Aug 2013
Print article
A compound found in soybeans may become an effective HIV treatment, which could eliminate the drug resistance problems faced by current therapies, according to new research.

Genistein, derived from soybeans and other plants, shows potential in suppressing the HIV infection, according to Dr. Yuntao Wu, an infectious diseases and the department of molecular and microbiology professor with the George Mason University (Fairfax, VA, USA)-based US National Center for Biodefense.

Nevertheless, that does not mean individuals should begin eating large amounts of soy products. “Although genistein is rich in several plants such as soybeans, it is still uncertain whether the amount of genistein we consume from eating soy is sufficient to inhibit HIV,” Dr. Wu said.

Genistein functions by blocking the communication from a cell’s surface sensors to its insides and is known as a tyrosine kinase inhibitor. These sensors, located on the cell’s surface, tell the cell about its environment and also communicate with other cells. HIV uses some of these surface sensors to trick the cell to send signals inside. These signals change cell structure so that the virus can get inside and spread infection.

However, genistein blocks the signal and stops HIV from finding a way inside the cell. It takes a different approach than the conventional antiretroviral drug used to suppress HIV. “Instead of directly acting on the virus, genistein interferes with the cellular processes that are necessary for the virus to infect cells,” Dr. Wu noted. “Thus, it makes the virus more difficult to become resistant to the drug. Our study is currently it its early stage. If clinically proven effective, genistein may be used as a complement treatment for HIV infection.”

Dr. Wu sees possibilities in this plant-based approach, which may address drug toxicity issues as well. Because genistein is plant-derived, it may be able to sidestep drug toxicity, a common byproduct of the daily and lifelong pharmaceutical regimen faced by patients with HIV to keep the disease at bay, according to Dr. Wu. Typically, patients take a combination of multiple drugs to inhibit the virus. The frequency can lead to drug toxicity. Furthermore, HIV mutates and becomes drug-resistant.

Dr. Wu and his team are now looking for ways to determine how much genistein is required to inhibit HIV. Because there is a possibility that plants may not have high enough levels, this agent would need to be refined and further developed.

Related Links:

George Mason University

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.